AMYLOID A GENE FAMILY EXPRESSION IN DIFFERENT MOUSE TISSUES

By R. L. MEEK and E. P. BENDITT

From the Department of Pathology, University of Washington, Seattle, Washington 98195

Serum amyloid A (SAA)¹ is a family of acute phase proteins (1–3), unique among these in being an apoprotein of high density lipoprotein (HDL) (4, 5). In response to a variety of inflammatory conditions, plasma SAA levels are dramatically elevated several hundred to a thousandfold and may reach a concentration of 1 mg/ml (6–8). The various inflammatory stimuli are thought to elevate SAA via a common monocyte-derived circulating mediator (9). IL-1 has been identified as one such mediator (10–16). In the mouse, SAA is encoded by three genes (SAA₁, SAA₂, and SAA₃) and a pseudo gene (17). The liver is a major site of SAA synthesis where messenger RNA for each of the three genes is elevated 500–2,000-fold after LPS injection (18, 19). The SAA₁ and SAA₂ polypeptides are synthesized and secreted by hepatocytes (20–22) and constitute as much as 20% of the HDL apoprotein of mice challenged with LPS (23). The SAA₃ gene is a recent discovery (2), and identification of the polypeptide has not yet been reported.

SAA is perhaps more widely known as the precursor to amyloid A (AA) protein. It is the major component of amyloid fibrils deposited in tissues in the disease amyloidosis associated with chronic inflammation (4, 5, 24–27). Of the three possible SAA gene products, murine AA protein is derived from only SAA₂ (9) by a mechanism that selectively removes it from the circulating pool of both SAA₁ and SAA₂ (22). Though liver is considered to be the major if not the only source of SAA, some reports (28–30) have suggested extrahepatic sites of synthesis, particularly the spleen, and that deposit of AA in amyloidosis is mediated via local synthesis. Using a murine SAA cDNA, we have previously shown (22) that the spleen is not active in synthesizing SAA mRNA during splenic amyloid deposit induced by repeated casein injections in mice. We wished to determine if the three individual members of the SAA gene family in the liver respond to inflammation induced by different inflammatory agents and if any of the SAA genes are expressed in extrahepatic tissues. We found differential hepatic SAA response to these agents; casein elevated hepatic SAA₁ and SAA₂ mRNA while LPS elevated all three. Extrahepatic SAA mRNA was also found, primarily after LPS injection, and several qualitative and quantitative patterns of SAA₁, SAA₂, and SAA₃ mRNA expression are evident among these tissues. It is clear that the SAA gene family does not exhibit a simple all-or-none response

¹This work was supported by National Institutes of Health (Bethesda, MD) grant HL-03174.

¹Abbreviations used in this paper: AA, amyloid A; HDL, high density lipoprotein; SAA, serum amyloid A.
to casein- or LPS-induced inflammation but exhibits a diverse expression of individual members of the family; this varies among tissues and between the two inflammatory agents used.

Materials and Methods

RNA Preparation and Northern Blot Analysis. Male BALB/c mice 2–3 mo of age were given an intraperitoneal injection of LPS (50 μg in 0.5 ml of PBS) or a subcutaneous injection of casein (0.5 ml of a 10% solution). 18 h after injection, animals were killed and we removed the appropriate tissues. Peritoneal macrophages were elicited by injecting 2 ml of sterile thioglycolate intraperitoneally. 2 d later we injected 10 μg of LPS intraperitoneally, and after another day cells were collected by peritoneal lavage, washed in PBS, and plated in petri dishes at 2 x 10^6 cells/60-mm dish in RPMI medium containing 20% FCS. After 1 h, attached cells were washed and scraped from the plates in PBS and pelleted for RNA extraction. Liver for time course data was obtained from BALB/c mice after LPS injection and CBA mice after casein injection. Total RNA was isolated from fresh tissues or cells after polytron homogenization in 5 M guanidinium isothiocyanate and LiCl precipitation (31) as described elsewhere (32). RNA was denatured and electrophoresed through 1.5% agarose containing 2.2 M formaldehyde (33) and transferred to Gene Screen Plus nylon membrane (New England Nuclear, Boston, MA) (34). Blots were incubated in hybridization solution (35) modified to include salmon sperm DNA (20–40 μg/ml) and polyethylene glycol 6000 (10%). After 3–4 hr blots were hybridized with 1 x 10^6 cpm/ml of nick-translated 32P-labeled SAA cDNA (36) for 16 hr at 42°C, washed as described previously (14), and exposed to X-ray film (Kodak XAR-5) at -70°C apposed to an intensifying screen (DuPont Cronex lightning plus).

Oligonucleotide Probes. To distinguish between SAA, SAA 2, and SAA 3 mRNA, oligonucleotide probes specific for each were synthesized (courtesy of Howard Hughes Medical Institute, DNA Synthesis Laboratory, University of Washington). All three probes were designed from a region in the 3' untranslated sequences beginning 14 nucleotides after the termination codon where all three genes are divergent (3), as shown in Fig. 2a; these are distinct from the oligonucleotides used by Yamamoto et al. (37). Uniqueness of each oligonucleotide for their respective mRNA was checked by searching each of the three SAA mRNA sequences for regions of homology to each of the oligonucleotide sequences (Sequence Homology Search Program, International Biotechnologies Inc., New Haven, CT). Oligonucleotides were end-labeled with T4 polynucleotide kinase (Bethesda Research Laboratories, Gaithersburg, MD) following the manufacturer's directions, except that 10 pmol of oligonucleotide were reacted in a 10-μl reaction with 50 μCi [γ-32P] ATP (3,000–4,000 Ci/mmol). Oligonucleotides were separated from unincorporated [γ-32P]ATP by chromatography through P-10 resin (Bio-Rad Laboratories, Richmond, CA) in 10 mM Tris (pH 7.5), 100 mM NaCl, 2 mM EDTA, 10 μg/ml yeast tRNA (32). Probe-specific activity of 2–4 x 10^6 cpm/pmol was regularly obtained, assuming 100% recovery of oligonucleotide.

Denaturing gel electrophoresis and blotting analysis was performed as described above. Prehybridization was performed in 6× SSC (1X = 105 mM NaCl, 15 mM Na citrate), 5X Denhardt's solution, 0.5% SDS, 100 μg/ml yeast tRNA, and 0.05% NaPP at 45°C for 1–4 h. End-labeled oligonucleotide probes were heated at 65°C for 5 min, diluted to 3–5 ng/ml in hybridization solution (as above except with 0.1% SDS). Blots were hybridized with oligonucleotide for 16 h at 45°C, then washed at room temperature in 6X SSC, 0.1% SDS three times for 20 min followed by one wash at 45°C for 5 min. Autoradiography was then carried out as described above.

The melting temperature (T_m) for SAA, and SAA 2 oligonucleotide is 52°C, while that of the SAA 3 oligomer is 54°C (38). For oligomer hybrids <20 nucleotides long, the T_m is reduced 5°C for each mismatched base pair. SAA 1 and SAA 2 probes are mismatched at 4 positions, while the SAA 3 probed is mismatched at 12 and 15 positions compared with complimentary regions of the SAA 1 and SAA 2 probes, respectively. Therefore, hybridization was performed at 45°C, which is 7°C below the T_m of SAA 1 and SAA 2 oligomers.
Fig. 1. Representative Northern blot of SAA mRNA in several mouse tissues. (a) 5 μg of total RNA from each tissue, except 0.5 μg of liver RNA, 18 h after injection with casein or LPS, were denatured, electrophoresed, blotted, and hybridized with ³⁵P-labeled SAA cDNA as described under procedures: (1) unstimulated; (2) casein; (3) LPS. A typical autoradiograph is shown. (b) As in a except the autoradiograph exposure was three times longer, and (1) unstimulated; (2) LPS.

and only 2°C below the temperature recommended for perfectly matched molecules (38). Under these conditions, each oligonucleotide probe should hybridize specifically to their respective mRNAs. Evidence of the specificity of these probes is seen in Fig. 3, where the pattern of expression is distinctly different among most tissues.

Results

The relative amount of SAA mRNA in 14 murine tissues was examined after casein or LPS injection by hybridization of Northern blots with recombinant mouse SAA1 cDNA. The resultant pattern of SAA mRNA expression after casein injection is quite different from the pattern after LPS injection (Fig. 1). Casein stimulated ~1,000-fold elevation of hepatic SAA mRNA compared with un.injected controls (Table I). Of the remaining 13 tissues, casein induced SAA mRNA elevation only in the adrenal gland. SAA mRNA was detected in small and large intestine, but at a level equivalent to the unstimulated quantity. In contrast to the limited effect of casein on tissues, LPS elicited SAA mRNA accumulation in all tissues examined (Table I). As with casein injection, liver was stimulated ~1,000-fold after LPS injection. Extrahepatic tissues exhibit a broad range of SAA levels from trace amounts in pancreas and brain to modest amounts in the large intestine, kidney, and lung. A more detailed examination of small intestines revealed a gradient of response to LPS (Fig. 1); only trace amounts could be detected in the duodenum, while the jejunum contained ~0.5% and ileum ~5% of hepatic levels (Table I). Three major regions of the brain were also examined for differential SAA mRNA levels (cerebrum, cerebellum and pons, medulla and stem), and were found to express equal levels of SAA mRNA (data not shown).

We used separate oligonucleotide probes designed from the 3'-untranslated portion of each SAA messenger RNA (Fig. 2a) to assess the specific SAA1, SAA2,
TABLE I
Relative Levels of Mouse SAA mRNA Induced by LPS or Casein

| Tissue                          | Control | Casein | LPS |
|---------------------------------|---------|--------|-----|
| Liver                           | 0.1     | 100    | 100 |
| Adrenal                         | 0       | 0.5    | 2.0 |
| Large intestine                 | 1.5     | 1.0    | 9.0 |
| Small intestine                 | 0.2     | 0.2    | 1.0 |
| Duodenum                        | 0       | ND     | 0   |
| Jejunum                         | 0.1     | ND     | 0.5 |
| Ileum                           | 0.5     | ND     | 5.0 |
| Kidney                          | 0       | 0      | 5.0 |
| Lung                            | 0       | 0      | 2.5 |
| Testes, skeletal muscle, stomach, spleen, heart, pancreas, brain, pituitary | 0       | 0      | 0.05* -0.5 |

Total RNA was prepared from individual tissues, except pituitary and adrenal glands which were pooled from 6-10 animals. 5 µg of RNA were examined by Northern blot analysis. Filters were hybridized with 32P-labeled SAA cDNA as in Fig. 1. Each filter contained 5, 0.5, 0.05, and 0.005 µg of 18-h post-LPS total liver RNA as standards. Various exposures of the resulting autoradiographs were analyzed by quantitative scanning densitometry. Absorbances in the linear range of the film exposure were compared with absorbances of the liver RNA standards. Relative values are expressed as percent of that found in 18-h post-LPS liver RNA. The 5' end of our SAA1 cDNA (pSAA1) contains a highly conserved region (100%) spanning amino acid residues 32-44 (5, 17) and represents 12% of pSAA1 length. The remaining pSAA1 sequence 5' to this conserved sequence is ~45% homologous to SAA1 but >90% homologous to SAA2 mRNA. Only nick-translated SAA1 cDNA fragments complementary to the highly conserved region of SAA3 mRNA will be stable under the hybridization and wash conditions used. Therefore SAA3 mRNA is detected with ~12% the sensitivity of SAA1 and SAA2 mRNA.

* Plasmid pSAA1 could detect mRNA in as little as 2.5 ng of total RNA from mouse liver 18 h after injection of LPS. This represents ~3 SAA1, 3 SAA2, and 24 SAA3 mRNA molecules per hepatocyte, assuming 6,000 molecules of each SAA mRNA per hepatocyte as reported by Lowell (18), and establishes the lower limits of SAA mRNA detection in these experiments. These data were determined from one set of tissues. RNA from most tissues has been isolated in one more or up to three more experiments with similar results.

or SAA3 mRNA expression in hepatic and extrahepatic tissues. The time course of liver mRNA expression for SAA1, SAA2, and SAA3 after casein or LPS injections are shown in Fig. 2b. SAA1 and SAA2 mRNAs exhibit essentially the same time course after a single casein injection; they were only slightly elevated by 4 h (3%), followed by a gradual rise to ~25% of the maximum level by 9 h. The maximum level was reached by 16 h, where they remained through 29 h. SAA3 mRNA was minimally elevated by casein injection and reached only 3% of the maximum SAA1 and SAA2 levels. The accumulation of SAA1 and SAA2 mRNA after LPS injection was much more rapid than after casein injection. They were both near maximal elevation by 4 h (90%) and remained elevated up to 29 h when the levels began to decline (70%). At 48 h, SAA1 and SAA2 mRNA were ~15% of the maximum level after 9 and 16 h. The SAA3 mRNA was expressed at a high level compared with casein injection, but accumulated at a
FIGURE 2. Hepatic SAA, SAA2, and SAA3 mRNA detected with oligonucleotide probes. (a) Nucleotide sequences of SAA1, SAA2, and SAA3 message-strand DNA (reference 3) from which complementary oligonucleotide probes were designed. (b) Time course of hepatic SAA1, SAA2, and SAA3 mRNA accumulation after LPS or casein injection. Mice received a single injection of LPS or casein and total RNA was isolated at the indicated times from individual livers after LPS injection or from pairs of livers after casein injection. Filters were hybridized with 32P-labeled oligonucleotide probes as described under Materials and Methods. A representative autoradiograph is shown. Quantitative densitometry of several autoradiographs was performed as in Table I, and absorbances were calculated relative to the density of liver RNA 16 h after LPS injection.

slower rate than that of LPS-induced SAA1 and SAA2, reaching 25% of the maximum level at 4 h, 50% by 9 h, and the maximum equal to SAA2 by 16 h; disappearance is slightly faster than that of SAA1 and SAA2 mRNA so that by 48 h the level is reduced to 3%. The different rate of SAA1 and SAA2 mRNA accumulation induced by casein compared with LPS injection was also observed in the time course of SAA accumulation in the circulation determined by RIA in groups of four animals at each point (data not shown).

Analysis of extrahepatic tissue also revealed distinct patterns of SAA1, SAA2, and SAA3 gene expression (Fig. 3). The tissues can be grouped into three patterns (Table II): (a) tissues expressing all three genes (liver and kidney), (b) tissues expressing SAA1 and SAA3 (small and large intestine), and (c) tissues that express predominantly or only SAA3 (adrenal gland, lung, spleen, heart, testis, stomach, skeletal muscle, brain, pituitary gland, pancreas, peritoneal macrophages). Liver and kidney express all three mRNAs with the liver exhibiting
nearly equal amounts of each one. In the kidney, all SAA mRNAs were lower than liver and exhibit a distinct fourfold difference between SAA1 (20%) and SAA2 (5%) (Table II). SAA2 was not detected in the small or large intestine, while SAA1 was low and SAA3 substantial. Analysis of the duodenum, jejunum, and ileum revealed a different quantitative pattern for SAA1 and SAA3 expression (Table II). SAA3 levels varied by only approximately threefold between them, but SAA1 was very prominent in the ileum, being 10-fold higher than in jejunum and not detected at all in duodenum. Of the remaining tissues, lung and adrenal gland expressed high levels of SAA3 (60 and 35%) and low levels of SAA1 and SAA2. Low levels of SAA2 were found in skeletal muscle and stomach while SAA3 levels were moderate and SAA1 was not detected. SAA1 and SAA2 mRNA was not detected in the remaining tissues, but we found different levels of SAA3: peritoneal macrophages, 100%; testis, heart, and spleen, 25–35%; and pancreas and brain 1–2% of hepatic levels.

Discussion

The differences in tissue expression of the three SAA mRNAs, the different time course in liver, and the differing tissue response to specific acute-phase stimulants raise a new set of questions about the mode of regulation at the molecular level of this family of genes and the possible functions of their products. A variety of stimuli, including tissue injury and inflammatory agents, are effective in elevating SAA levels. The different stimuli are thought to act at least in part

![Image of Northern blot with bands labeled SAA1, SAA2, and SAA3]
through a common macrophage/monocyte-derived mediator or mediators (14, 16, 21); IL-1 has been identified as a mediator of SAA induction (10–13). Whether monokines besides IL-1 are involved in SAA production is not known. The data reported here indicate that there is more than one factor responsible for the induction of the several SAA genes. The most notable fact is that SAA₃ gene expression is different from SAA₁ and SAA₂. Thus hepatic SAA₃ mRNA is expressed at high levels in response to LPS but is expressed only at a low level after casein administration. Moreover, the majority of extrahepatic tissues respond only to LPS and then mainly with expression of SAA₂ mRNA. Besides IL-1, macrophages and monocytes secrete other monokines, including lymphotoxin, IFN-γ, tumor necrosis factor, and glucocorticoid-antagonizing factor in response to bacterial infection or endotoxin administration (39, 40). Perhaps one or several of these factors is involved in control of SAA₃ mRNA expression.

SAA₃ RNA is expressed in a wide variety of tissues at levels ranging over 100-fold between liver and brain (Table II). This differential behavior raises the following question: are the differentiated cells of these tissues responsible for SAA₃ mRNA expression or is it expressed by a single dispersed cell system present in these tissues? For this role there are several candidate cells: (a) endothelial or (b) smooth muscle cells of the vasculature, or (c) resident tissue

---

**Table II**

Relative Levels of SAA₁, SAA₂ and SAA₃ mRNA in Different Tissues after Casein or LPS Injection

| Tissue            | SAA₁ | SAA₂ | SAA₃ | SAA₁ | SAA₂ | SAA₃ |
|-------------------|------|------|------|------|------|------|
| Liver             | 100  | 100  | 2    | 100  | 100  | 100  |
| Kidney*           | 20   | 5    | 11   |      |      |      |
| Large intestine*  | 1    | 0    | 0    | 4.5  | 0    | 25   |
| Small intestine*  | 0.5  | 0    | 0    | 1    | 0    | 10   |
| Duodenum          | 0    | 0    | 3    |      |      |      |
| Jejunum           | 1    | 0    | 7    |      |      |      |
| Ileum             | 15   | 0    | 10   |      |      |      |
| Adrenal           | 0    | 0    | 2    | 1    | 2    | 35   |
| Lung*             | 1    | 0.5  | 60   |      |      |      |
| Spleen*           | 0    | 0    | 25   |      |      |      |
| Heart*            | 0    | 0    | 30   |      |      |      |
| Testis*           | 0    | 0    | 12   |      |      |      |
| Skeletal muscle*  | 0    | 1    | 8    |      |      |      |
| Stomach*          | 0    | 0.5  | 7    |      |      |      |
| Brain, pituitary,* pancreas* | 0  | 0   | 1    |      |      |      |
| Macrophages*      | 0    | 0    | 100  |      |      |      |

20 µg of total RNA from each tissue or 2 µg of macrophage RNA were examined by Northern blot analysis as in Fig. 3. Autoradiograph exposures in the linear response range were examined by quantitative densitometry and absorbances were compared with those of standards constructed with total post-LPS (18-h) liver RNA as described for Table I.

* These tissues do not respond to casein.

† Values are relative to total liver RNA 18 hr after LPS injection.

‡ Lowest detectable SAA mRNA levels correspond to 30 molecules/hepatocyte, assuming 6,000 molecules of each SAA mRNA per hepatocyte (18).
macrophages. We found after LPS stimulation that RNA from peritoneal macrophages contain as much SAA\textsubscript{2} mRNA as that found in liver RNA (Table II); moreover, thioglycollate-elicited macrophages did not express elevated SAA mRNA in response to casein (data not shown), as is the case with all extrahepatic tissue except adrenal gland. Fixed macrophages may be responsible for production of the SAA\textsubscript{3} mRNA in some tissues like lung, but in others, heart and testis for example, this seems unlikely because the macrophage population is low, while SAA\textsubscript{3} levels are quite substantial. It is also of interest that endothelial cells elaborate a variety of inflammatory mediators including IL-1 in response to LPS (41). Could they also express SAA\textsubscript{3}? Whether tissue macrophages and other members of the reticuloendothelial system express SAA\textsubscript{3} mRNA in response to LPS and whether they alone are responsible for extrahepatic tissue SAA\textsubscript{3} mRNA remains to be determined.

The small intestine is interesting; the SAA\textsubscript{1} level varied only threefold over its length after LPS injection, while SAA\textsubscript{1} was expressed most dramatically in the ileum (Table II). In addition, SAA\textsubscript{1} mRNA was detected in control ileum and large intestine. Perhaps the presence of gram-negative bacteria and their production of endotoxin in these regions of the intestinal tract cause SAA\textsubscript{1} expression in otherwise unstimulated control animals and this is only moderately enhanced after LPS injection.

A recent report by Ramadori et al. (42) using a cDNA common to all three SAA mRNAs showed accumulation of SAA mRNA in the spleen after LPS injection. The authors suggested local production of SAA as a source of AA protein. However, this is not the case since murine AA protein is derived from only the SAA\textsubscript{2} polypeptide (9) and the spleen expresses only the SAA\textsubscript{3} mRNA (Table II). Furthermore, in a previous report (22) no SAA mRNA was detected in the spleen during casein-induced splenic amyloid accumulation.

Our finding that hepatic SAA\textsubscript{3} mRNA reached a level equivalent to that of SAA\textsubscript{1} and SAA\textsubscript{2} mRNA after LPS injection differs from the data of Yamamoto et al. (37). They reported that SAA\textsubscript{3} mRNA was barely detectable while SAA\textsubscript{1} and SAA\textsubscript{2} mRNA were expressed at high levels. The reason for this discrepancy is not clear. Perhaps this discrepancy is a result of the different sets of oligonucleotide probes used or because Yamamoto et al. analyzed RNA levels 24 h after LPS injection when the SAA\textsubscript{3} mRNA levels were declining.

The widespread pattern of tissues expressing SAA\textsubscript{3} messenger RNA resembles that of apoE mRNA expression (43), while the pattern of SAA\textsubscript{1} and SAA\textsubscript{2} mRNA expression resembles more closely the restricted pattern of A-1 mRNA (44). Differences in tissue expression and gene responses to acute-phase stimuli suggest that SAA\textsubscript{3} may have a different function from that of the SAA\textsubscript{1} and SAA\textsubscript{2}. Structural evidence points to SAA\textsubscript{1} and SAA\textsubscript{2} having a selective affinity for certain lipids, as indicated by their association with particular lipoprotein subclasses (20, 23). Is it possible that SAA\textsubscript{3} also has a special affinity for certain lipids? We have not yet found, nor have others reported, evidence of SAA\textsubscript{3} protein in the circulation; perhaps the SAA\textsubscript{3} polypeptide remains cell bound. Of interest is the fact that the putative SAA\textsubscript{3} signal peptide (9) contains a core region of hydrophobic and uncharged residues like other signal peptides (45); however, it contains glutamine at position −1, a very unusual amino acid at this position.
In addition, the putative signal peptide cleavage site has a low processing probability (46). If SAA₃ is not secreted, it could be involved with intracellular lipid and other lipophilic substance transport.

The present study provides information on the variety of tissues capable of synthesizing SAA mRNAs and the differential expression of the three murine SAA genes. Further studies are necessary to: (a) identify the cell type(s) responsible for extrahepatic SAA mRNA synthesis, particularly SAA₃; (b) determine whether SAA₃ is secreted or remains intracellular as a first step in elucidating its function; and (c) elucidate the mechanisms and determine the factors involved in the control of SAA₁, SAA₂, and SAA₃ mRNA expression.

Summary

Serum amyloid A (SAA) is a major acute-phase reactant and apoprotein of high density lipoprotein (HDL). SAA is encoded by a family of three active genes. We examined hepatic expression and searched for extrahepatic expression of the three SAA mRNAs after injection with casein or LPS. Studies using an SAA cDNA, which detects all three SAA mRNAs, revealed that after casein injection liver SAA mRNA was elevated ~1,000-fold. Adrenal gland expressed SAA mRNA at a low level (0.5% of hepatic level), and was the only extrahepatic tissue with elevated SAA mRNA after casein injection. The small intestine, primarily the ileum, and the large intestine of unstimulated control animals contained 5- and 15-fold higher SAA mRNA levels than control liver. LPS also elevated liver SAA mRNA ~1,000-fold. However, in contrast to casein injection, every extrahepatic tissue examined expressed SAA mRNA. Lung and kidney contained 2-5% and large intestine contained nearly 10% of SAA mRNA levels found in liver RNA. SAA mRNA levels were lower in the remaining tissues and ranged from 0.1% in the brain and pancreas to 1.0% in the small intestine, with the ileum containing 50-fold more than the duodenum.

Analysis of liver with SAA₁, SAA₂, and SAA₃ mRNA-specific oligonucleotide probes revealed that SAA₁ and SAA₂ mRNA were elevated ~50-fold higher than SAA₃ mRNA after casein administration. LPS, however, induced all three SAA mRNAs equally. In extrahepatic tissues, SAA₁, SAA₂, and SAA₃ mRNAs were expressed differentially and can be grouped into three general classes: (a) tissues expressing all three genes, (b) tissues expressing SAA₁ and SAA₃, and (c) tissues expressing predominantly or only SAA₃.

We thank Marlene Wambach for technical assistance, Ginny Wejak for manuscript preparation, and Tom Barrett and Paul Haydock for helpful comments.

Received for publication 28 August 1986.

References

1. Sipe, J. D., H. R. Colton, G. Goldberger, M. D. Edye, B. F. Tack, A. S. Cohen, and A. S. Whitehead. 1985. Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry. 24:2931.

2. Stearman, R. S., C. A. Lowell, C. G. Peltzman, and J. F. Morrow. 1986. The sequence and structure of a new serum amyloid A gene. Nucleic Acids Res. 14:797.
3. Yamamoto, K., and S. Migita. 1985. Complete primary structures of two major murine amyloid A proteins deduced from cDNA sequences. *Proc. Natl. Acad. Sci. USA.* 82:2915.

4. Benditt, E. P., and N. Eriksen. 1977. Amyloid protein SAA is associated with high density lipoprotein from human serum. *Proc. Natl. Acad. Sci. USA.* 74:4025.

5. Benditt, E. P., N. Eriksen, and R. H. Hanson. 1979. Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. *Proc. Natl. Acad. Sci. USA.* 76:4092.

6. Kushner, I. 1982. The phenomenon of the acute phase response. *Ann. NY Acad. Sci.* 389:39.

7. Benson, M. D., M. S. Scheinber, T. Shirahama, L. S. Cathcart, and M. Skinner. 1977. Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. *J. Clin. Invest.* 59:412.

8. McAdam, K. P. W. J., and J. D. Sipe. 1976. Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. *J. Exp. Med.* 144:1121.

9. Hoffman, J. S., L. H. Ericsson, N. Eriksen, K. A. Walsh, and E. P. Benditt. 1984. Murine tissue amyloid protein AA N-terminal sequence identity with only one of two serum amyloid proteins (ApoSAA) gene products. *J. Exp. Med.* 159:641.

10. Sztein, M. B., S. N. Vogel, J. D. Sipe, P. A. Murphy, S. B. Mizel, J. J. Oppenheim, and D. L. Rosenstreich. 1981. The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. *Cell. Immunol.* 65:164.

11. McAdam, K. P. W. J., J. L. Knowles, N. T. Ross, C. A. Dinarello, L. J. Rosenwasser, M. J. Selinger, M. M. Kaplan, and R. Goodman. 1982. The biology of SAA: identification of the induces, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies. *Ann. NY Acad. Sci.* 389:126.

12. Sipe, J. D., S. N. Vogel, M. B. Sztein, M. Skinner, and A. S. Cohen. 1982. The role of interleukin I in acute phase serum amyloid A (SAA) and serum amyloid P (SAP) biosynthesis. *Ann. NY Acad. Sci.* 389:137.

13. Dinarello, C. A. 1984. Induction of acute phase reactants by interleukin-I. *Adv. Inflammation Res.* 8:203.

14. Selinger, M. J., K. P. W. J. McAdam, M. M. Kaplan, J. D. Sipe, S. N. Vogel, and D. L. Rosenstreich. 1980. Monokine-induced synthesis of serum amyloid A protein by hepatocytes. *Nature (Lond.)*. 285:498.

15. Rosenstreich, D. L., and K. P. W. J. McAdam. 1979. Lymphoid cells in endotoxin induced production of the amyloid-related serum protein SAA. *Infect. Immun.* 23:181.

16. Sipe, J. D., S. N. Vogel, J. L. Ryan, K. P. W. J. McAdam, and D. L. Rosenstreich. 1979. Detection of a mediator derived from endotoxin-stimulated macrophages that induces the acute phase serum amyloid A response in mice. *J. Exp. Med.* 150:597.

17. Lowell, C. A., D. A. Potter, R. S. Steraman, and J. F. Morrow. 1986. Structure of the murine serum amyloid A gene family. *J. Biol. Chem.* 261:8442.

18. Lowell, C. A., R. S. Steraman, and J. F. Morrow. 1986. Transcriptional regulation of serum amyloid A gene expression. *J. Biol. Chem.* 261:8453.

19. Morrow, J. F., R. S. Steraman, C. G. Pelzman, and D. A. Potter. 1981. Induction of hepatic synthesis of serum amyloid A protein and actin. *Proc. Natl. Acad. Sci. USA.* 78:4718.

20. Hoffman, J. S., and E. P. Benditt. 1982. Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high density lipoprotein in primary mouse hepatocyte culture. *J. Biol. Chem.* 257:10518.
21. Benson, M. D., and L. Kleiner. 1980. Synthesis and secretion of serum amyloid protein A (SAA) by hepatocytes in mice treated with casein. J. Immunol. 124:495.
22. Meek, R. L., J. S. Hoffman, and E. P. Benditt. 1986. Amyloidogenesis: one serum amyloid A isotype is selectively removed from the circulation. J. Exp. Med. 163:499.
23. Hoffman, J. S., and E. P. Benditt. 1982. Changes in high density lipoprotein content following endotoxin administration in the mouse. J. Biol. Chem. 257:10510.
24. Benditt, E. P., and N. Eriksen. 1981. Chemical classes of amyloid substance. Am. J. Pathol. 65:291.
25. Rosenthal, C. J., E. C. Franklin, B. Frangione, and J. Greenspan. 1976. Isolation and partial characterization of SAA - an amyloid-related protein from human serum. J. Immunol. 116:1415.
26. Pepys, M. B., and M. L. Baltz. 1983. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 34:141.
27. Levin, M., E. C. Franklin, B. Frangione, and M. Pros. 1972. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J. Clin. Invest. 51:2773.
28. Baumal, R., S. Sklar, B. Wilson, and R. Laskov. 1978. Casein-induced murine amyloidosis in vitro by monolayer explants of casein-injected mice. Lab. Invest. 39:632.
29. Cohen, A. S., E. Gross, and T. Shirahama. 1965. The light and electron microscopic autoradiographic demonstration of local amyloid formation in spleen extracts. Am. J. Pathol. 47:1079.
30. Franklin, E. C., G. Lavie, and D. Zucker-Franklin. 1981. Speculations on the pathogenesis of the amyloid diseases. In Immunological Aspects of Aging. D. Segre and L. Smith, editors. Marcel Dekker, Inc., New York. 433–444.
31. Cathala, G., J.-F. Savouret, B. Mendes, B. L. West, M. Karin, J. A. Martil, and J. D. Baxter. 1983. A method for isolation of intact, translationally active ribonucleic acid. DNA (NY) 2:529.
32. Benditt, E. P., N. Eriksen, and R. L. Meek. 1987. Serum amyloid A protein. Methods Enzymol. In press.
33. Lehrack, H., D. Diamond, J. M. Wozney, and H. Boedtker. 1977. RNA molecular weight determinations by gel electrophoresis under denaturing conditions: a critical reexamination. Biochemistry. 16:4743.
34. Thomas, P. S. 1980. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc. Natl. Acad. Sci. USA. 77:5201.
35. Amasino, R. 1986. Acceleration of nucleic acid hybridization rate by polyethylene glycol. Biochemistry. 152:304.
36. Maniatis, T., A. Jeffrey, and P. G. Kleid. 1975. Nucleotide sequence of the rightward operator of phage λ. Proc. Natl. Acad. Sci. USA. 72:1184.
37. Yamamoto, K., M. Shiroo, and S. Migita. 1986. Diverse gene expression for isotypes of murine serum amyloid A protein during acute phase reaction. Science (Wash. DC). 237:227.
38. Meinloth, J., and G. Wahl. 1984. Hybridization of nucleic acids immobilized on solid supports. Anal. Biochem. 138:267.
39. Berry, L. J. 1977. Bacterial endotoxins. CRC. Critical Rev. Toxicol. 5:239.
40. Rosenstreich, D. L. 1981. The macrophage. In Cellular Functions in Immunity and Inflammation. J. J. Oppenheim, D. L. Rosenstreich, and M. Potter, editors. Elsevier/North-Holland, New York. 127–160.
41. Moisesc, P., D. Cavender, and M. Ziff. 1986. Production of interleukin 1 by human endothelial cells. J. Immunol. 136:2486.
42. Ramadori, G., J. D. Sipe, and H. Colten. 1985. Expression and regulation of the murine serum amyloid A (SAA) gene in extrahepatic sites. J. Immunol. 135:3645.
43. Elshourbagy, N. A., W. S. Liaov, R. W. Mahley, and J. Taylor. 1985. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA. 82:205.
44. Elshourbagy, N. A., M. S. Boguski, W. S. Liaov, L. S. Jefferson, J. I. Gordon, and J. M. Taylor. 1985. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc. Natl. Acad. Sci. USA. 82:8242.
45. Kreil, G. Transfer of proteins across membranes. Annu. Rev. Biochem. 50:317.
46. Von Heyne, G. 1983. Patterns of amino acids near signal-sequence cleavage sites. Eur. J. Biochem. 133:17.